ACM
ORKA

Aster Capital Management’s Oruka Therapeutics ORKA Stock Holding History

Aster Capital Management’s Portfolio ORKA Stock Details ORKA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-25
Closed -$758 – 1420
2025
Q4 		$758 Buy
+25
New +$697 ﹤0.01% 1015
2025
Q1 		– Sell
-5
Closed -$97 – 1738
2024
Q4 		$97 Buy
+5
New +$122 ﹤0.01% 1071

Other funds holding ORKA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return

Aster Capital Management's ORKA Position: Q1 2026 in Review

Aster Capital Management sold out of Oruka Therapeutics (ORKA) in Q1 2026, closing a stake of 25 shares — an estimated $758 sold.

Aster Capital Management first reported a position in ORKA in Q4 2024 and held it in 2 quarters. The position peaked at $758 in Q4 2025. 184 funds tracked by Wall St. Rank hold ORKA as of Q1 2026.

  • Aster Capital Management reported no remaining Oruka Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Aster Capital Management sold 25 Oruka Therapeutics shares in Q1 2026, an estimated $758.
  • Aster Capital Management first reported a position in Oruka Therapeutics in Q4 2024 and held it in 2 quarters.
  • Aster Capital Management's Oruka Therapeutics position peaked at $758 in Q4 2025.
  • 184 funds tracked by Wall St. Rank held Oruka Therapeutics as of Q1 2026.

Based on Aster Capital Management's 13F filing for Q1 2026, filed 13 May 2026.